Literature DB >> 36071765

An effective model for screening moderate-to-severe obstructive sleep apnea based on the STOP-BANG questionnaire.

Yuyu Wang1,2,3, Juanjuan Zou1,2,4, Huajun Xu1,2, Cuiping Jiang5, Hongliang Yi1,2, Jian Guan1,2, Shankai Yin1,2.   

Abstract

Background: This study aimed to develop a more effective screening model for moderate-to-severe obstructive sleep apnea (OSA) based on the best tool among Epworth Sleepiness Scale (ESS), NoSAS score and STOP-BANG questionnaire (SBQ).
Methods: This study screened 2,031 consecutive subjects referred with suspected OSA from 2012 to 2016, including the test cohort from 2012 to 2014 and the validation cohort from 2014 to 2016. Anthropometric measurements, polysomnographic data, ESS, NoSAS scores and SBQ scores were recorded. Receiver operating characteristic curve analyses were performed and the final predictive models were verified in a validation cohort.
Results: A total of 1,840 adults were finally included. The performance of ESS, NoSAS score and SBQ in screening OSA was compared. The diagnostic accuracy of SBQ was superior to ESS and NoSAS. A predictive model based on SBQ yielded an area under the curve (AUC) of 0.931 (95% CI: 0.915-0.946), and the sensitivity and specificity were 84.47 (95% CI: 81.4-87.2) and 87.36 (95% CI: 83.9-90.3) respectively. In the validation cohort, the AUC was 0.955 (95% CI: 0.938-0.969), with a sensitivity and specificity of 86.79 (95% CI: 83.2-89.9) and 90.88 (95% CI: 87.2-93.8) respectively. In addition, the model performed moderately in screening mild OSA with the AUC being 0.771 (95% CI: 0.721-0.815). Conclusions: The SBQ was effective in screening moderate-to-severe OSA. And a SBQ -based predictive model afforded excellent diagnostic efficacy, which could be applied in clinical practice. 2022 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Obstructive sleep apnea (OSA); STOP-BANG questionnaire (SBQ); screening model; sensitivity; specificity

Year:  2022        PMID: 36071765      PMCID: PMC9442538          DOI: 10.21037/jtd-20-2027

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   3.005


Introduction

Obstructive sleep apnea (OSA) is a chronic sleep disorder characterized by a marked reduction or complete cessation of airflow during sleep, affecting 3–24% of the general population (1). It significantly reduces the quality of life and increases the risks of metabolic disorders, hypertension, cardiovascular disease, stroke, and traffic accidents (2-4). Moderate-to-severe OSA, the prevalence of which is 1–14%, is more commonly associated with risks of hypertension, coronary artery disease, and dysfunctional metabolism than mild OSA (5,6), early screening and diagnosis of moderate-to-severe OSA is thus important. However, epidemiological studies have shown that the prevalence of the undiagnosed condition among general populations is as high as 93% in males and 82% in females (7). Although overnight polysomnography (PSG) remains the gold standard for OSA diagnosis, it is difficult to schedule this for snorers given the enormous pressure on hospitalization in China. PSG is expensive and requires a dedicated setup. Moreover, professional staff require extensive training, and the process is time-consuming. All of these factors contribute to the poor diagnosed prevalence. Portable sleep monitor is a cost-effective alternative to PSG, but it is still more expensive and complicated compared with questionnaire survey, and it may underestimate the severity of OSA and potentially yield false-negative results (8). Thus, a simple screening tool for moderate-to-severe OSA is urgently required. Tools including Epworth Sleepiness Scale (ESS), NoSAS score, and STOP-BANG questionnaire (SBQ) are commonly used to screen for OSA. The ESS yields a subjective measure of excessive daytime sleepiness, and has been widely used to predict OSA (9), but some authors have argued that it is ineffective (10). NoSAS is a new and effective screening tool, but it has been frequently reported to be of insufficient accuracy (11). The SBQ is recognized as one of the best means for OSA screening, but the specificity is unsatisfactory and the results are rather inconsistent (12,13). Also, cutoff applicable to all populations has not been defined (14). New predictive models have recently been reported, but most of them are complicated with poor specificity and inconsistency, which often require biochemical parameters (10,12). Therefore, we performed a large-scale study to develop a simple and effective screening tool for moderate-to-severe OSA based on the best questionnaire among ESS, NoSAS score and SBQ by evaluating their diagnostic efficiency. We present the following article in accordance with the STARD reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-20-2027/rc).

Methods

Study design and population

The total cohort consisted of consecutive subjects admitted to the Sleep Center of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital with suspected OSA from 2012 to 2016. Consecutive subjects from 2012 to 2014 were enrolled in test cohort and subjects from 2014 to 2016 were enrolled in validation cohort. The inclusion criteria included: (I) subjects were suspected to be suffered from OSA; (II) age ≥18 years. We excluded those previously treated for OSA, those with malignancy, psychiatric disorder, narcolepsy and upper airway resistance syndrome and those for whom any clinical data were missing (). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethic Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital [No. 2019-KY-050(K)]. Informed consent was obtained from all individual participants included in the study.
Figure 1

Flow diagram of recruitment and exclusion of participants. OSA, obstructive sleep apnea; ESS, Epworth Sleepiness Scale; SBQ, STOP-BANG questionnaire; PSG, polysomnography.

Flow diagram of recruitment and exclusion of participants. OSA, obstructive sleep apnea; ESS, Epworth Sleepiness Scale; SBQ, STOP-BANG questionnaire; PSG, polysomnography.

Anthropometric measurements and physical examination

Anthropometric measurements including neck circumference (NC), waist circumference (WC) and hip circumference (HC) were measured following standardized protocols. The body mass index (BMI) was the weight divided by the height squared. Blood pressure was measured on the morning after PSG by trained nurses using mercury sphygmomanometers after each patient had rested for at least 5 min in a quiet environment and the result was the average value of three measurements.

Questionnaire

All subjects were requested to complete a questionnaire exploring personal information, alcohol consumption and smoking histories, and any prior illnesses and medical treatments. The ESS explores subjective sleepiness in eight situations (15). Respondents use a four-point scale [0-3] to respond to each of the eight questions, and the scores are summed to give an overall score from 0–24. The NoSAS score has been widely used including Chinese (16,17), and the final score can range from 0–17, with 4 points for an NC ≥40 cm; 3 for a BMI 25–30 kg/m2 or 5 for a BMI ≥30 kg/m2; 2 for snoring; 4 for age ≥55 years; and 2 for being male. The SBQ features eight questions exploring snoring (S), tiredness (T), observed breathing cessation (O), blood pressure (P), BMI (B), age (A), NC, and gender (G) with better performance in Chinese (18,19).

Overnight PSG

Each subject underwent overnight laboratory-based PSG (Alice 4 or 5 platform; Respironics, Pittsburgh, PA, USA). We performed electroencephalography, electro-oculography, submental and anterior tibialis electromyography, and electrocardiography; we measured thoracic and abdominal movements, oronasal airflow, and oxygen saturation. All PSG recordings were completed by the same skilled technician using standard criteria. All PSG recordings less than 4 h were repeated or excluded. Respiratory events were carefully scored using the American Academic Sleep Medicine (AASM) criteria. The apnea hypoxia index (AHI) was the number of apnea and hypopnea events per hour of sleep. Subjects with AHI ≥15 were considered to have moderate-to-severe OSA.

Statistical analysis

All statistical analysis was performed with the aid of SPSS ver. 21.0 software (SPSS, Chicago, IL, USA). Dichotomous variables were expressed as percentages and continuous variables as means ± standard deviations (SDs); skewed variables were expressed as medians ± interquartile ranges. The significance of between-group differences in baseline characteristics was examined using the Mann-Whitney U-test, the Wilcoxon rank sum test, or the χ2 test. Logistic regression analyses were performed to derive odds ratios with 95% confidence intervals [ORs (95% CIs)] for moderate-to-severe OSA. Receiver operating characteristic (ROC) curves were drawn to assess the diagnostic accuracy of ESS, NoSAS and SBQ evaluations, and that of the predictive model. Sensitivities and specificities were also recorded. Youden’s index (sensitivity + specificity − 1) was used to determine cutoffs maximizing diagnostic utility. A P value <0.05 was considered to be significance.

Results

Baseline characteristics

In total, 1,840 consecutive subjects were enrolled, of whom 1,087 were in the test cohort and 753 in the validation cohort (). The basic characteristics of all subjects are shown in . Males were more obese and tended to have a higher AHI and more severe hypoxia than females. Females had lower BMI, NC, WC, and HC, and lower triglyceride and low-density lipoprotein levels than males in both cohorts (all P<0.05). The fasting blood glucose levels significantly differed by gender in test cohort while the difference was not significant in validation cohort. In contrast, the serum level of total cholesterol significantly differed by gender in validation cohort while the difference was not significant in test cohort. The ESS, NoSAS, and SBQ scores were significantly higher in males than females (all P<0.001).
Table 1

Basic characteristics of test cohort and validation cohort stratified by gender

CharacteristicTest cohortValidation cohort
Males (n=863)Females (n=224)PMales (n=571)Females (n=182)P
Age (years)41 (33.0–50.0)48 (39.0–57.0)<0.00137 (31.0–49.0)46 (35.0–56.0)<0.001
BMI (kg/m2)26.7 (24.5–29.0)23.9 (22.0–27.3)<0.00126.2 (24.2–28.4)24.2 (21.9–27.6)<0.001
NC (cm)40.0 (38.0–42.0)34.0 (32.6–37.0)<0.00140.0 (38.0–42.0)34.0 (32.9–37.0)<0.001
WC (cm)96.0 (90.0–102.0)86.0 (79.0–94.0)<0.00195.0 (90.0–101.0)86.0 (78.4–95.0)<0.001
HC (cm)100.0 (96.0–105.0)96.0 (91.0–101.0)<0.001101.0 (96.5–105.0)96.0 (91.0–104.0)<0.001
Sleep data
   AHI (times/h)29.4 (9.0–55.0)6.5 (0.8–24.1)<0.00127.2 (6.7–55.3)5.3 (1.2–19.0)<0.001
   Moderate-to-severe OSA (n, %)567, 65.777, 34.4<0.001371, 6553, 29.1<0.001
   LSpO2 (%)80.0 (69.0–88.0)88.5 (80.0–93.0)<0.00182.0 (72.0–89.0)89.0 (82.0–93.1)<0.001
   Mean SpO2 (%)94.8 (92.5–96.2)96.0 (94.0–97.5)<0.00190.0 (67.0–95.0)96.0 (95.0–97.0)<0.001
Blood data
   FBG (mmol/L)5.19 (4.86–5.56)5.04 (4.68–5.54)0.0115.18 (4.89–5.60)5.10 (4.70–5.74)0.140
   TC (mmol/L)4.67 (4.12–5.34)4.60 (4.08–5.24)0.7234.54 (3.99–5.19)4.39 (3.70–4.98)0.015
   TG (mmol/L)1.55 (1.10–2.23)1.05 (0.75–1.53)<0.0011.60 (1.13–2.31)1.16 (0.75–1.69)<0.001
   HDL (mmol/L)0.99 (0.87–1.12)1.19 (1.02–1.40)<0.0010.98 (0.87–1.11)1.12 (0.97–1.30)<0.001
   LDL (mmol/L)2.90 (2.42–3.42)2.75 (2.33–3.24)0.0392.75 (2.34–3.31)2.54 (1.97–3.19)0.001
Questionnaires
   ESS8.0 (4.0–13.0)5.0 (2.0–9.8)<0.0018.0 (3.0–12.0)3.0 (0–8.0)<0.001
   NoSAS7.0 (5.0–11.0)3.0 (0–6.0)<0.0017.0 (4.0–11.0)3.0 (0–5.0)<0.001
   SBQ4.0 (3.0–5.0)1.0 (1.0–3.0)<0.0013.0 (2.0–5.0)1.0 (0–2.0)<0.001

Dichotomous variables were expressed as percentage, and skewed variables were expressed as medians (interquartile range). The height and weight were recorded in meters and kilograms respectively, with accuracies of 0.01 m and 0.1 kg; NC, WC and HC were recorded in centimeters with accuracies of 0.1 cm. BMI, body mass index; NC, neck circumference; WC, waist circumference; HC, hip circumference; AHI, apnea-hypopnea index; OSA, obstructive sleep apnea; LSpO2, lowest oxygen saturation; mean SaO2, mean oxygen saturation; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ESS, Epworth Sleepiness Scale; SBQ, STOP-BANG questionnaire; NoSAS, neck, obesity, snoring, age, sex.

Dichotomous variables were expressed as percentage, and skewed variables were expressed as medians (interquartile range). The height and weight were recorded in meters and kilograms respectively, with accuracies of 0.01 m and 0.1 kg; NC, WC and HC were recorded in centimeters with accuracies of 0.1 cm. BMI, body mass index; NC, neck circumference; WC, waist circumference; HC, hip circumference; AHI, apnea-hypopnea index; OSA, obstructive sleep apnea; LSpO2, lowest oxygen saturation; mean SaO2, mean oxygen saturation; FBG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ESS, Epworth Sleepiness Scale; SBQ, STOP-BANG questionnaire; NoSAS, neck, obesity, snoring, age, sex.

Performance of ESS, NoSAS, and SBQ

As shown in , the efficacy of SBQ used to predict moderate-to- severe OSA was better than those of the ESS and NoSAS; the area under the curve (AUC) was 0.843 (95% CI: 0.820–0.866), with a sensitivity 88.0% and a specificity 62.8%. After stratification by gender, SBQ remained optimal, with AUCs of 0.814 (95% CI: 0.787–0.840) in males and 0.865 (95% CI: 0.813–0.907) in females. A gender-related difference in optimal diagnostic SBQ cutoffs was significant, the values of which were 3 for males and 1 for females ().
Table 2

The efficiency of ESS, NoSAS and STOP-BANG in predicting moderate to severe OSAHS

QuestionnaireAll (n=1,087)Males (n=863)Females (n=224)
AUC (95% CI)Cut-off valueSensitivity/specificity (%)AUC (95% CI)Cut-off valueSensitivity/specificity (%)AUC (95% CI)Cut-off valueSensitivity/specificity (%)
ESS0.683 (0.650–0.716)675.2/51.40.666 (0.633–0.698)669.4/54.30.683 (0.617–0.745)755.4/71.1
NoSAS0.758 (0.729–0.787)6.568.5/70.20.706 (0.669–0.743)9.546.0/84.80.805 (0.744–0.867)4.567.5/79.6
SBQ0.843 (0.820–0.866)388.0/62.80.814 (0.787–0.840)372.5/75.70.865 (0.813–0.907)185.7/70.8

ESS, Epworth Sleepiness Scale; AUC, area under the curve; OSAHS, obstructive sleep apnea-hypopnea syndrome; CI, confidence interval; SBQ, STOP-BANG questionnaire; NoSAS, neck, obesity, snoring, age, sex.

ESS, Epworth Sleepiness Scale; AUC, area under the curve; OSAHS, obstructive sleep apnea-hypopnea syndrome; CI, confidence interval; SBQ, STOP-BANG questionnaire; NoSAS, neck, obesity, snoring, age, sex.

A predictive model based on SBQ

As SBQ yielded the optimal diagnostic accuracy in terms of predicting moderate-to-severe OSA, we developed a predictive model to maximize diagnostic accuracy. Due to the fact that BMI, age, gender, and NC were all included in SBQ, the model incorporated other parameters including WC, HC, the lowest SpO2% (LSpO2) other than SBQ score. After multiple regression analysis, the predictive model included WC, LSpO2, and the SBQ score; the Logit (P) was 0.449 × SBQ + 0.023 × WC – 0.194 × LSpO2 + 12.787. The AUC of the constructed model was 0.931 (95% CI: 0.915–0.946), and the sensitivity and specificity were 84.47 (95% CI: 81.4–87.2) and 87.36 (95% CI: 83.9–90.3) respectively ( and ). Then the model was testified in the validation cohort. The AUC was 0.955 (95% CI: 0.938–0.969), with a sensitivity and specificity of 86.79 (95% CI: 83.2–89.9) and 90.88 (95% CI: 87.2–93.8) respectively ( and ).
Table 3

Performance of the final model in the test and validation cohort

CohortAUC (95% CI)Sensitivity (%)Specificity (%)PPV (%)NPV (%)+LR–LR
Test cohort0.931 (0.915–0.946)84.47 (81.4–87.2)87.36 (83.9–90.3)90.7 (88.1–92.9)79.5 (75.6–83.0)6.68 (6.4–7.0)0.18 (0.1–0.2)
Validation cohort0.955 (0.938–0.969)86.79 (83.2–89.9)90.88 (87.2–93.8)92.5 (89.4–94.9)84.2 (80.0–87.9)9.52 (9.0–10.0)0.15 (0.10–0.2)

AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; –LR, negative likelihood ratio.

Figure 2

ROC curves for the final model in the test cohort and validation cohort. (A) The AUC in the test cohort was 0.931 (95% CI: 0.915-0.946); (B) The AUC in the test cohort was 0.955 (95% CI: 0.938-0.969). ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval.

AUC, area under the curve; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; –LR, negative likelihood ratio. ROC curves for the final model in the test cohort and validation cohort. (A) The AUC in the test cohort was 0.931 (95% CI: 0.915-0.946); (B) The AUC in the test cohort was 0.955 (95% CI: 0.938-0.969). ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval. Considering the possibility of mild OSA aggravation, screening mild patients is also important. Therefore, we investigated the performance of the model in screening overall OSA including mild patients. As shown in Table S1, the model performed excellently in screening overall OSA with the AUC being 0.926 (95% CI: 0.904–0.943), and performed moderately in screening mild OSA with the AUC being 0.771 (95% CI: 0.721–0.815).

Discussion

In the present large-scale study, we found that the SBQ was effective when used to screen for moderate-to-severe OSA, and it performed better than the ESS and NoSAS in this context. The predictive model based on SBQ, WC and LpO2 afforded excellent diagnostic efficiencies. Given the severity of the condition and the low diagnosis rate, some studies have focused on screening for moderate-to-severe OSA using questionnaires such as the ESS, NoSAS, and SBQ (20,21). ESS is often used to assess subjective sleepiness (15); higher scores are associated with an increased risk of metabolic syndrome in males with OSA (22). Although the ESS is widely used to screen for OSA, its diagnostic reliability has been questioned. Kum et al. (23) found that ESS scores increased as AHI thresholds increased, but some studies have found weak or no correlations between ESS scores and OSA severity, suggesting that the ESS may not aid in OSA diagnosis (10,24). We found that the ESS did not reliably predict moderate-to-severe OSA, in agreement with Miller and Ghandeharioun et al. (10,24). Maybe it was because that the ESS is totally subjective and influenced by many factors including daytime naps and blood pressure (25,26). The NoSAS, which measures five items objectively, is a new and effective screening tool affording better performance, and has been validated in an external population (16,17). It was demonstrated that the NoSAS exhibited good predictive performances in both European and Asian populations (17,27). However, Giampá et al. (11) found that the NoSAS was inaccurate when used to diagnose OSA in patients with resistant hypertension. We found that the NoSAS yielded a better AUC but had a low sensitivity in terms of predicting moderate and severe OSA, perhaps because some subjective symptoms are also usefully predictive. SBQ is a part-self-administered questionnaire based on the Berlin instrument, and includes both subjective symptoms and objective indicators; the design is thus more reasonable than that of the ESS. SBQ is an acronym derived from the first letters of the questions (18,19), facilitating completion of the instrument. Many researchers consider SBQ to be one of the best measures for OSA screening. Chiu et al. (20), in a meta-analysis of various questionnaires, concluded that SBQ optimally screened for OSA. A recent report also indicated that SBQ was diagnostically more accurate than the ESS (10). However, similar to most questionnaires, SBQ affords high sensitivity but only low specificity when diagnosing mild, moderate, and severe OSA (12,13), and no one cutoff is appropriate for all populations (14,18). We found that SBQ was moderately effective when used to predict moderate-to-severe OSA, and the performance was better than ESS and NoSAS. An AASM task force evaluated the current screening tools, and concluded that no single tool was ideal (28). Therefore, development of a predictive model affording adequate sensitivity and specificity became urgent. Simpson et al. (29) reported that a combination of snoring frequency and hypertension status could be used to identify those with moderate-to-severe OSA in general populations, but the sample size was small and diagnosis of moderate-to-severe OSA was not PSG-based. Sun et al. (30) used an artificial intelligence model to screen for moderate-to-severe OSA. The sensitivity and specificity were satisfactory, but only 120 patients were evaluated. We built a new model based on SBQ data, WC and LSpO2 that are readily available. The AUCs, sensitivities, and specificities for both males and females were good. In the validation cohort, model performance was excellent. Although we enrolled a relatively large number of subjects, our work had certain limitations. Firstly, the prevalence of OSA in subjects referred to our sleep center was higher than that in the general population, which may compromise the generalization of our model. Secondly, ethnicity or menopausal status may affect sleepiness in females with suspected OSA. Significantly, in our sample, the percentage and severity of female OSA were much lower than that of male OSA, but the situation may be different in other samples and the predictive value will be affected as the prevalence of moderate to severe OSA changes among samples. Therefore, the diagnostic efficiency of our model must be further verified in other samples including different country of residence and ethnicity. In conclusion, the SBQ performed excellently in screening moderate-to-severe OSA. And a predictive model that combined SBQ with WC and LpO2 afforded excellent diagnostic efficiency, which provided a simple and effective screening tool for OSAHS. The article’s supplementary files as
  30 in total

1.  The utility of home sleep apnea tests in patients with low versus high pre-test probability for moderate to severe OSA.

Authors:  Cathy A Goldstein; Hala Karnib; Katherine Williams; Zunaira Virk; Afifa Shamim-Uzzaman
Journal:  Sleep Breath       Date:  2017-11-22       Impact factor: 2.816

2.  Detecting sleep apnoea syndrome in primary care with screening questionnaires and the Epworth sleepiness scale.

Authors:  Chamara V Senaratna; Jennifer L Perret; Adrian Lowe; Gayan Bowatte; Michael J Abramson; Bruce Thompson; Caroline Lodge; Melissa Russell; Garun S Hamilton; Shyamali C Dharmage
Journal:  Med J Aust       Date:  2019-05-03       Impact factor: 7.738

3.  The STOP-BANG questionnaire shows an insufficient specificity for detecting obstructive sleep apnea in patients with atrial fibrillation.

Authors:  Asmaa M Abumuamar; Paul Dorian; David Newman; Colin M Shapiro
Journal:  J Sleep Res       Date:  2018-04-22       Impact factor: 3.981

4.  Persistent Obstructive Sleep Apnea Burden on Family Finances and Quality of Life.

Authors:  Mathieu Bergeron; Stacey L Ishman
Journal:  Otolaryngol Head Neck Surg       Date:  2021-01-19       Impact factor: 3.497

Review 5.  Diagnostic accuracy of the Berlin questionnaire, STOP-BANG, STOP, and Epworth sleepiness scale in detecting obstructive sleep apnea: A bivariate meta-analysis.

Authors:  Hsiao-Yean Chiu; Pin-Yuan Chen; Li-Pang Chuang; Ning-Hung Chen; Yu-Kang Tu; Yu-Jung Hsieh; Yu-Chi Wang; Christian Guilleminault
Journal:  Sleep Med Rev       Date:  2016-11-05       Impact factor: 11.609

6.  Comparisons of measures used to screen for obstructive sleep apnea in patients referred to a sleep clinic.

Authors:  Jennifer N Miller; Kevin A Kupzyk; Lani Zimmerman; Bunny Pozehl; Paula Schulz; Debra Romberger; Ann M Berger
Journal:  Sleep Med       Date:  2018-06-28       Impact factor: 3.492

7.  Sleep-disordered breathing in community-dwelling elderly.

Authors:  S Ancoli-Israel; D F Kripke; M R Klauber; W J Mason; R Fell; O Kaplan
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

8.  A new suggestion for the Epworth Sleepiness Scale in obstructive sleep apnea.

Authors:  Rauf Oguzhan Kum; Müge Özcan; Nurcan Yurtsever Kum; Yavuz Fuat Yılmaz; Volkan Güngör; Adnan Ünal
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-10       Impact factor: 2.503

Review 9.  Obstructive Sleep Apnea, Hypertension, and Cardiovascular Risk: Epidemiology, Pathophysiology, and Management.

Authors:  Liann Abu Salman; Rachel Shulman; Jordana B Cohen
Journal:  Curr Cardiol Rep       Date:  2020-01-18       Impact factor: 2.931

10.  Diagnostic performance of the STOP-Bang questionnaire as a screening tool for obstructive sleep apnea in different ethnic groups.

Authors:  Rida Waseem; Matthew T V Chan; Chew Yin Wang; Edwin Seet; Stanley Tam; Su Yin Loo; Carmen K M Lam; David S Hui; Frances Chung
Journal:  J Clin Sleep Med       Date:  2021-03-01       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.